News

Patients who had received placebo treatment experienced a 0.22% HbA1c reduction, six months post-treatment. Post prandial and AUC (area under the curve) glucose showed improvement versus placebo but

The study evaluated the efficacy and safety of Orencia in patients six to 17 years of age with moderate to severe active pJIA, who had an inadequate response

Raghav Chari, senior vice president of proprietary products business at Dr Reddy’s, said: “We are extremely pleased to be working with Aegis and gaining access to their patented

Jim Jersey, president and CEO at Agilux, said: “In launching the LC/MS/MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery,

The phase III clinical trial was a multi-center, randomised, double-blind, placebo-controlled study. Dose levels of 100 – 1600mcg were tested in the trial. In the double-blind portion of

The Phase 1 trial is an open label, multicenter, dose escalation study of Telintra in combination with lenalidomide in patients with non-deletion (5q-) low to intermediate-1 risk MDS.

The company claims that it is simple to use and employs analytical methodology based on established pharmacopoeial techniques for transdermal patches. It provides information that allows developers to

AMT has concluded two clinical studies for LPLD in Europe and Canada. Long term follow-up from both of these is ongoing, as is a third clinical study in

The company claims that the studies conducted by researchers in the US, including the Centers for Disease Control and Prevention (CDC), showed that antibody-only tests fail to identify